12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

TaiGen, Zhejiang Medicine sales and marketing update

TaiGen granted Zhejiang Medicine exclusive rights to commercialize and manufacture nemonoxacin in China, excluding Hong Kong and Macau. TaiGen will receive an $8 million...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >